Anagenex's precision small molecule discovery platform leverages AI to design and custom chemistry to synthesize 100M target-specific for testing in two weeks, creating a virtuous cycle between real lab experiments and computational tools.

The company’s pipeline is focused on synthetic lethal oncology.